Anti-HIV Activity of the Neurokinin-1 Receptor Antagonist Aprepitant and Synergistic Interactions with other Antiretroviralsĭouglas, S.D., Leeman, S.E. Manak M, Moshkoff M, Nguyen L, Meshki J, Tebas P, Tuluc F, and Douglas SDD. Immune Suppression and Immune Activation in Depression. Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor. Monaco-Shawver, L., Schwartz, L., Tuluc, F., Guo, CJ., Lai, JP, Gunnam, SM., Kilpatrick, LE, Banerjee, PP, Douglas, SD, Orange. Serguei Spitsin, Ph.D., Senior Research Associateįlorin Tuluc, M.D., Ph.D., Research Assistant Professor Mohammad Khan, MBBS, PhD, Senior Research Associate He is a Member ASCI, American Academy Microbiology, Honorary Life Member Society for Leukocyte Biology, Fellow AAAS. He was the Recipient of Abbott Immunology, Neter, Conason, and Redway Awards. He is the Founding Editor-in-Chief of Clinical and Diagnostic Laboratory Immunology, American Society Microbiology. He has chaired committees for the VA, FDA (Blood Products Advisory Committee) and Chair NIH-CSR (AIDS Immunology Pathogenesis Study Section). Douglas has been President, Society for Leukocyte Biology. He is testing NK1R antagonists as therapy for HIV patients.ĭr. He detected SP-preferring receptor, neurokinin-1 (NK1R), in monocytes, and that SP antagonists inhibit HIV. He developed methods for isolation-differentiation of blood monocytes into macrophages and showed the role of macrophages in HIV. Douglas discovered pokeweed mitogen as a lymphocyte stimulator and developed tests to diagnose immune deficiency diseases. Ongoing studies have demonstrated associations between substance P, impaired natural killer cell activity and depression in HIV-infected individuals.Įarly in his career, Dr. He has recently instigated studies involving psychosocial and psychiatric interactions with the immune and nervous systems. Douglas has extensive experience in cellular and humoral immunologic studies, including studies of AIDS infection and of primary immunodeficiencies. His laboratory is actively involved in research in cellular immunology and its relationship to the immunopathogenesis of HIV. He has also demonstrated up-regulation of substance P by HIV. He discovered the truncated from of NK1-R in human cells and demonstrated that SP antagonists block HIV through CCR5 and he has applied as NK1R antagonists novel HIV therapy. Douglas' ongoing research program involves molecular and cellular immunologic studies of substance P and its receptor, Neurokinin-1 in monocyte-macrophages. The Douglas laboratory does basic, translational, and clinical research.ĭr. These networks are state-of-the-art therapeutic trials for adult and pediatric HIV/AIDS throughout the world. He is also the PI for the Adolescent Trial Network (NICHD). Douglas’ laboratory is the central immunology laboratory for the IMPAACT Network, and a specialty immunology laboratory. He is the Principal Investigator for the Philadelphia International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Unit, which includes a Clinical Research Site at CHOP, Clinical Research Site at the Adult Unit at the Hospital of the University of Pennsylvania, and two Satellites (Hospital of the University of Pennsylvania and Pennsylvania Hospital)(NIAID). He and his group investigate the interaction between neuropeptides, monocyte-macrophages and HIV. He is the PI for a U01, Anti-HIV Neuroimmunomodulatory Therapy with Neurokinin-1 Antagonists (NIMH) (through 2014), which encompasses three Projects (including a clinical trial) and two Cores (including Pharmacology and Biostatistics). His laboratory is funded by a longstanding R01,Tachykinins Mononuclear Phagocytes and HIV-1 Infection. Douglas has been investigating cellular immune mechanisms and monocyte-macrophages. Key words: Substance P, Neurokinin-1 Receptorĭr. Interaction between immune system and brain and HIV, Neurokinin-1R (SP Receptor) Antagonists for HIV Therapy, HIV and NK1-R immune activation and suppression in psychiatric disease. Description of Research Expertise Research Interests
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |